• S Georgin-Lavialle, V Hentgen, M E Truchetet, M Romier, M Hérasse, H Maillard, M Pha, P Pillet, H Reumaux, A Duquesne, J P Larbre, and A Belot.
• Sorbonne Université, Service de médecine interne, Centre de Référence des Maladies Auto-Inflammatoire et de l'Amylose inflammatoire (CeRéMAIA), Hôpital Tenon, 4, rue de la Chine, Paris, France. Electronic address: sophie.georgin-lavialle@aphp.fr.
• Rev Med Interne. 2021 Sep 1; 42 (9): 633-638.

AbstractAutoimmune and autoinflammatory diseases (AIDs) are a heterogeneous group of diseases. They can occur in childhood and account for significant morbidity and mortality. Transitioning from pediatric to adult healthcare can be difficult for patients and their families. It can interfere with patient follow-up and management, and eventually lead to complications. Although recommendations exist for the successful transition of patients with chronic diseases, few are specifically adapted to children and adults with AIDs (Suris et al., 2015-Solau-Gervais, 2012). The French working group on transition of the rare autoimmune and autoinflammatory diseases presents its reflections and recommendations for a successful transition. Preparation for transition should start early. Its goals are to empower adolescents by providing them with the knowledge to manage their own care, respond appropriately to changes in their condition, and evolve within the adult healthcare system. This requires the active participation of the patient, his or her family, as well as the pediatric and adult medical teams. The transition process involves multidisciplinary care and dedicated therapeutic education programs. Finally, the identification of medical specialists by region, trained in rare AIDs and accompanied by expert patients, may improve the management of patients with rare AIDs from adolescence to adulthood.Copyright © 2021 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

21 keywords...

hide…